Esreboxetine
Esreboxetine is a selective norepinephrine reuptake inhibitor (NRI) that was being developed as a potential treatment for major depressive disorder (MDD) and attention deficit hyperactivity disorder (ADHD). It is the (S,S)-enantiomer of reboxetine, which is a racemic mixture used as an antidepressant.
Pharmacology[edit | edit source]
Esreboxetine works by inhibiting the reuptake of norepinephrine (NE) into the presynaptic neuron, thereby increasing the concentration of norepinephrine in the synaptic cleft. This action is believed to contribute to its antidepressant and cognitive-enhancing effects. Unlike some other antidepressants, esreboxetine has minimal effects on the reuptake of serotonin and dopamine.
Clinical Development[edit | edit source]
Esreboxetine was investigated in clinical trials for the treatment of major depressive disorder and attention deficit hyperactivity disorder. However, its development was discontinued due to insufficient efficacy in clinical trials compared to existing treatments.
Side Effects[edit | edit source]
The side effects of esreboxetine are similar to those of other norepinephrine reuptake inhibitors. Common side effects include:
Comparison with Reboxetine[edit | edit source]
Esreboxetine is the (S,S)-enantiomer of reboxetine, which means it is a more selective form of the drug. Reboxetine is a racemic mixture containing both (R,R)- and (S,S)-enantiomers. The (S,S)-enantiomer is believed to be more pharmacologically active, which led to the development of esreboxetine as a potentially more effective treatment.
Discontinuation[edit | edit source]
Despite initial promise, esreboxetine was discontinued in clinical development. The decision was based on the results of clinical trials that did not demonstrate a significant advantage over existing treatments for major depressive disorder and attention deficit hyperactivity disorder.
See Also[edit | edit source]
- Norepinephrine reuptake inhibitor
- Reboxetine
- Major depressive disorder
- Attention deficit hyperactivity disorder
References[edit | edit source]
External Links[edit | edit source]
-
 | This medical article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
